mCRC | mBC | mNSCLC | mRCC | mOC | mCC | Total | ||||||||||
Year 1 | No of patients | Cost | No of patients | Cost | No of patients | Cost | No of patients | Cost | No of patients | Cost | No of patients | Cost | No of patients | Cost | ||
Without biosimilars | Original | 4607 | €134 552 572 | 314 | €9 046 010 | 338 | €19 482 624 | 25 | €1 430 348 | 1592 | €55 141 009 | 128 | €7 380 788 | 7004 | €227 033 352 | |
With biosimilars | Original | 3225 | €127 702 501 | 220 | €8 585 477 | 236 | €18 490 764 | 17 | €1 357 529 | 1114 | €52 333 781 | 90 | €7 005 032 | 4902 | €215 475 084 | |
Biosimilar | 1382 | 94 | 101 | 7 | 478 | 38 | 2100 | |||||||||
Incremental cost | −€6 850 071 | −€339 719 | −€991 860 | −€72 819 | −€2 807 229 | −€375 756 | −€11 558 268 | |||||||||
Budget impact | −5.1% | |||||||||||||||
Year 2 | Without biosimilars | Original | 7094 | €207 192 952 | 444 | €12 815 181 | 478 | €27 600 384 | 38 | €2 178 292 | 2396 | €82 971 757 | 172 | €9 904 642 | 10 622 | €342 663 209 |
With biosimilars | Original | 3547 | €189 581 552 | 222 | €11 725 890 | 239 | €25 254 352 | 19 | €1 993 137 | 1198 | €75 919 158 | 86 | €9 062 748 | 5311 | €313 536 836 | |
Biosimilar | 3547 | 222 | 239 | 19 | 1198 | 86 | 5311 | |||||||||
Incremental cost | −€17 611 401 | −€1 089 290 | −€2 346 033 | −€185 155 | −€7 052 599 | −€841 895 | −€29 126 373 | |||||||||
Budget impact | −8.5% | |||||||||||||||
Year3 | Without biosimilars | Original | 8081 | €236 020 306 | 477 | €13 757 473 | 513 | €29 629 824 | 43 | €2 459 408 | 2680 | €92 811 413 | 179 | €10 334 651 | 11 973 | €385 013 076 |
With biosimilars | Original | 1616 | €203 921 545 | 95 | €11 886 457 | 103 | €25 600 168 | 9 | €2 124 929 | 536 | €80 189 061 | 36 | €8 929 138 | 2395 | €332 651 297 | |
Biosimilar | 6465 | 382 | 411 | 34 | 2144 | 143 | 9579 | |||||||||
Incremental cost | −€32 098 762 | −€1 871 016 | −€4 029 656 | −€334 480 | −€12 622 352 | −€1 405 513 | −€52 361 778 | |||||||||
Budget impact | −13.6% |
mBC, metastatic breast cancer; mCC, metastatic cervical cancer; mCRC, metastatic colorectal cancer; mNSCLC, metastatic, unresecable or relapsed non-small cell lung cancer; mOC, metastatic epithelial ovarian, fallopian tube or peritoneal cancer; mRCC, metastatic renal cell carcinoma.